Home > Boards > US Listed > Biotechs > ArQule Inc. (ARQL)

$ARQL...been following their trial closely..

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
NSX Member Profile
Member Level 
Followed By 164
Posts 9,401
Boards Moderated 0
Alias Born 01/31/18
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 5:35:17 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/14/2020 12:20:35 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 5:03:56 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 12:05:45 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2020 1:43:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 11:29:38 AM
Termination of Registration of a Class of Security Under Section 12(g) (15-12g) Edgar (US Regulatory) - 1/27/2020 1:55:27 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/21/2020 6:00:55 AM
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire (US) - 1/6/2020 11:07:00 AM
WeissLaw LLP Investigates ArQule, Inc. PR Newswire (US) - 12/12/2019 3:49:00 PM
Merck, Sanofi Push To Add Cancer Drugs -- WSJ Dow Jones News - 12/10/2019 3:02:00 AM
Big Drugmakers Push Deeper Into Cancer Treatment -- 4th Update Dow Jones News - 12/9/2019 7:16:00 PM
Big Drugmakers Push Deeper Into Cancer Treatment -- 3rd Update Dow Jones News - 12/9/2019 4:37:00 PM
U.S. Stocks Slip as Trade War Weighs on Chinese Exports Dow Jones News - 12/9/2019 3:12:00 PM
Big Drugmakers Push Deeper Into Cancer Treatment -- 2nd Update Dow Jones News - 12/9/2019 2:33:00 PM
Merck to Buy ArQule for $2.7 Billion -- Update Dow Jones News - 12/9/2019 11:13:00 AM
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology... Business Wire - 12/9/2019 8:05:00 AM
(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price? PR Newswire (US) - 12/9/2019 7:37:00 AM
Merck to Buy ArQule for $2.7 Billion, or $20/Share Dow Jones News - 12/9/2019 7:26:00 AM
Merck to Acquire ArQule, Advancing Leadership in Oncology Business Wire - 12/9/2019 6:45:00 AM
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual ... Business Wire - 11/25/2019 7:00:00 AM
ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019 Business Wire - 11/13/2019 7:00:00 AM
ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversi... Business Wire - 11/6/2019 9:05:00 AM
NSX Member Level  Monday, 12/09/19 09:55:46 AM
Re: europtiger post# 333
Post # of 369 
$ARQL...been following their trial closely..

DD wins here

Make money

Invest wisely

My research and my opinion. My opinions is not a recommendation to buy or sell a security. Your decision whether or not to make a purchase should be based on your own due diligence.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist